Total Voting Rights
Shield Therapeutics plc has announced its total voting rights, confirming that its issued share capital comprises 1,074,157,593 ordinary shares of 1.5p each, with no shares held in treasury. This figure serves as the denominator for shareholders calculating notification requirements under the FCA's Disclosure Guidance and Transparency Rules.
Select text to share a quote on X · sign in to keep highlights & notes in your STX notes
London, UK, 30 September, 2026: Shield Therapeutics plc (LSE: STX), a commercial-stage pharmaceutical company specialising in iron deficiency confirms that in accordance with the requirements of the FCA's Disclosure and Transparency Rule 5.6.1, the Company's issued share capital consists of 1,074,157,593 ordinary shares of 1.5p each in issue, each with equal voting rights. No shares are held in treasury.
Clinically low iron levels (aka iron deficiency, ID) can cause serious health problems for children and adults of all ages, across multiple therapeutic areas. Together, ID and ID with anemia (IDA) affect about 20 million people in the US and represent a $2.3B market opportunity. As the first and only FDA approved oral iron to treat ID/IDA, ACCRUFeR® has the potential to meet an important unmet medical need for both physicians and patients and is now the #1 branded prescription oral iron in the US market today (*data source - IQVIA Xponent PlanTrak).
Cleaned text: letterheads, contacts and legal notices removed. View the original announcement ↗ · Company filings. Not investment advice.